vendredi 17 juin 2016

Onco Actu du 17 juin 2016

1. Biologie

Tumors have found a bloody new way to grow and spread [Science]

2.11 Etiologie - Alimentation

Coffee's cancer risk downgraded (as long as you don't drink it hot) [NHS Choices]

4. Dépistage, diagnostic et pronostic

Animated Dynamics Closes on $1.7M for Cancer Imaging Technology [Xconomy]

4.11 Dép., diag. & prono. - Ovaire

New technique could spot ‘invisible’ ovarian tumours during surgery [Cancer Research UK]

4.7 Dép., diag. & prono. - Col de l'utérus

QIAGEN launches QIAsure Methylation Test to determine cervical cancer risk [Qiagen]

5.12 Immunothérapies

First Human Test of CRISPR Proposed [MIT Technology Review]

5.2 Pharma

Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer [Merck]

Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer [The Street]

Merck's Keytruda prolongs life in big lung-cancer study [Reuters]

Scancell slumps as drug problem disrupts melanoma trial [Reuters]

5.3 Traitements - FDA, EMA,...

Adaptive pathways [EMA]

5.4 Traitements - Economie

Cotellic is Roche's latest cancer med to hit a snag at NICE [FiercePharma]

Pioneering cancer drug combination approved [BBC News]

Roche skin cancer drugs 'too expensive', says UK cost agency [Reuters]

Drug combination for fighting skin cancer approved for NHS use [The Guardian]

UK cost agency speeds approval of Bristol melanoma drug cocktail [Reuters]

6.1 Observation

Less educated women less likely to spot breast cancer symptoms [Cancer Research UK]

6.10 Politiques

The EU’s cancer community: better with the UK? [The Cancer Blog]

6.8 Communication

Puzzling Progress: What Strides Look Like in Cancer Research [CANCER RESEARCH Catalyst]